Advanced search
Publication Cover
Emerging Microbes & Infections Volume 12, 2023 - Issue 1
Submit an article Journal homepage
2,688
Views
6
CrossRef citations to date
0
Altmetric
Coronaviruses

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages

Hongjie Xiaa Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
Jason Yeunga Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
Birte Kalverama Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA;b Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
Cody J. Billsa Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
John Yun-Chung Chena Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
Chaitanya Kurhadea Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
Jing Zoua Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAView further author information
,
Steven G. Widena Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAORCID Iconhttps://orcid.org/0000-0002-6512-363XView further author information
ORCID Icon,
Brian R. Mannc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
Rebecca Kondorc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
C. Todd Davisc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
Bin Zhouc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
David E. Wentworthc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAView further author information
,
Xuping Xiea Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USACorrespondence[email protected] [email protected]
View further author information
&
Pei-Yong Shia Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA;d Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USA;e Sealy, Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX, USA;f Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA;g Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA;h Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USAView further author information
 show all
Article: e2161422 | Received 16 Nov 2022, Accepted 16 Dec 2022, Published online: 12 Jan 2023

References

  • Stegger M, Edslev SM, Sieber RN, et al. Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection. medRxiv. 2022. doi:10.1101/2022.02.19.22271112.
  • Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022 Aug;608(7923):593–602.
  • Hachmann NP, Miller J, Collier AY, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022 Jul 7;387(1):86–88.
  • Qu P, Faraone J, Evans JP, et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 subvariants. N Engl J Med. 2022 Jun 30;386(26):2526–2528.
  • Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: evidence from danish households. BioRxiv. 2022. doi:10.1101/2022.01.28.22270044.
  • Liu Y, Liu J, Shi PY. SARS-CoV-2 variants and vaccination. Zoonoses. 2022. doi:10.15212/ZOONOSES-2022-0001.
  • Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602:654–656.
  • Evans JP, Zeng C, Carlin C, et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci Transl Med. 2022 Mar 23;14(637):eabn8057.
  • Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by 3 doses of BNT162b2 vaccine or BA.1 infection. Emerg Microbes Infect. 2022 Dec;11(1):1828–1832.
  • Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596:273–275.
  • Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021 Apr 15;384(15):1466–1468.
  • Liu Y, Liu J, Xia H, et al. BNT162b2-Elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021 Jul 29;385(5):472–474.
  • Wang L, Kainulainen MH, Jiang N, et al. Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines. Nat Commun. 2022 Jul 27;13(1):4350.
  • Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022 Jun 23;13(1):3602.
  • Xie X, Zou J, Kurhade C, et al. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine. Cell Rep. 2022 Nov 29;41(9):111729.
  • Zou J, Xia H, Xie X, et al. Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. Nat Commun. 2022 Feb 9;13(1):852.
  • Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature. 2022 Mar;603(7902):679–686.
  • Xie X, Lokugamage KG, Zhang X, et al. Engineering SARS-CoV-2 using a reverse genetic system. Nat Protoc. 2021;16(3):1761–1784.
  • Xie X, Muruato A, Lokugamage KG, et al. An infectious cDNA clone of SARS-CoV-2. Cell Host Microbe. 2020 May 13;27(5):841–848 e3.
  • Liu Y, Liu J, Johnson BA, et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. Cell Rep. 2022 May 17;39(7):110829.
  • Liu J, Liu Y, Shan C, et al. Role of mutational reversions and fitness restoration in Zika virus spread to the americas. Nat Commun. 2021 Jan 26;12(1):595.
  • Liu Y, Liu J, Plante KS, et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022;602:294–299.
  • Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–121.
  • Shan C, Xia H, Haller SL, et al. A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission. Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20190–20197.
  • Johnson BA, Zhou Y, Lokugamage KG, et al. Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. PLoS Pathog. 2022 Jun;18(6):e1010627.
  • Liu Y, Zhang X, Liu J, et al. A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. Nat Commun. 2022 Jul 27;13(1):4337.
  • Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020 Aug 13;11(1):4059.
  • Liu Y, Liu J, Zou J, et al. Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes. Signal Transduct Target Ther. 2022 Aug 13;7(1):285.
  • Zou J, Kurhade C, Xia H, et al. Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2. Nat Commun. 2022 May 26;13(1):2956.
  • Smith DJ, Lapedes AS, de Jong JC, et al. Mapping the antigenic and genetic evolution of influenza virus. Science. 2004 Jul 16;305(5682):371–376.
  • Kurhade C, Zou J, Xia H, et al. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster. Nat Med. 2022: 2022/12/06.
  • Zou J, Kurhade C, Patel S, et al. Improved neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine. bioRxiv. 2022: 2022.11.17.516898.
  • Wolter N, Jassat W, Walaza S, et al. Clinical severity of SARS-CoV-2 omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nat Commun. 2022 Oct 4;13(1):5860.
  • Du X, Tang H, Gao L, et al. Omicron adopts a different strategy from Delta and other variants to adapt to host. Signal Transduct Target Ther. 2022 Feb 10;7(1):45.
  • Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity. Nature. 2022;603:706–714.
  • Barouch DH. Covid-19 vaccines - immunity, variants, boosters. N Engl J Med. 2022 Sep 15;387(11):1011–1020.
  • Redd AD, Nardin A, Kared H, et al. Minimal crossover between mutations associated with Omicron variant of SARS-CoV-2 and CD8(+) T-cell epitopes identified in COVID-19 convalescent individuals. mBio. 2022 Apr 26;13(2):e0361721.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.